CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 6,967 enrolled
Drug / intervention
EQ-5D-5Lother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07580092
NCT07580092N/ACompleted
CompareCT.gov

Construct Validity and Responsiveness of EQ-5D-3L and EQ-5D-5L in Patients With Inflammatory Joint Disease

Karolinska Institutet·observational·Posted May 12, 2026·Updated May 12, 2026

In Brief

An observational study evaluating EQ-5D-5L for Ankylosing Spondylitis and 4 related conditions. Completed, enrolled 6,967 participants across 1 site.

Detailed Summary

The aim of this study is to compare the construct validity (convergent validity and known-groups validity) and responsiveness of EQ-5D-3L and EQ-5D-5L in patients with inflammatory joint disease. The study is based on prospectively collected data through the Swedish Rheumatology Quality Register (SRQ).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis, Rheumatoid Arthritis (RA), Psoriatic Arthritis, Polyarthritis, Inflammatory Joint Disease (IJD)
CountriesSweden
CollaboratorsKarolinska University Hospital, The EuroQol Research Foundation

Timeline

N/ACompletedFinished
202420252026
First PostedMay 12, 2026
Enrollment StartNov 30, 2023
Primary CompletionMar 5, 2026
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 2 months ago

Interventions

EQ-5D-5Lother

EQ-5D is a generic instrument used to measure, value, and compare health across symptoms and diagnoses. There are two versions of the EQ-5D, the EQ-5D-3L and the EQ-5D-5: Patients with inflammatory joint disease already complete patient-reported measures (PROMs), including EQ-5D-3L, routinely in conjunction with their follow-up healthcare visits, and patients who consent to participate in the study will also complete the EQ-5D-5L. The order in which the patient responds to the EQ-5D-3L and EQ-5D-5L is randomised so that participants answer one version of the EQ-5D before the other routinely collected PROMs, and the other EQ-5D version at the end. When data collection with EQ-5D-5L is concluded, all data necessary for analyses will be retrieved from the SRQ.